Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib.

BACKGROUND: The aim of this study was to explore the relationship between follow-up imaging characteristics and overall survival (OS) in advanced hepatocellular carcinoma (HCC) patients under sorafenib treatment. METHODS: Associations between OS and objective response (OR) by mRECIST or early tumor shrinkage (ETS; ≥20% reduction in enhancing tumor diameter at the first follow-up imaging) were analyzed in HCC patients treated with sorafenib within a multicenter phase II trial (SORAMIC). 115 patients were included in this substudy. The relationship between survival and OR or ETS were explored. Landmark analyses were performed according to OR at fixed time points. Cox proportional hazards models with OR and ETS as a time-dependent covariate were used to compare survival with factors known to influence OS. RESULTS: The OR rate was 29.5%. Responders had significantly better OS than non-responders (median 30.3 vs. 11.4 months; HR, 0.38 [95% CI, 0.22-0.63], p < 0.001), and longer progression-free survival (PFS; median 10.1 vs. 4.3 months, p = 0.015). Patients with ETS ≥ 20% had longer OS (median 22.1 vs. 11.4 months, p = 0.002) and PFS (median 8.0 vs. 4.3 months, p = 0.034) than patients with ETS < 20%. Besides OR and ETS, male gender, lower bilirubin and ALBI grade were associated with improved OS in univariate analysis. Separate models of multivariable analysis confirmed OR and ETS as independent predictors of OS. CONCLUSION: OR according to mRECIST and ETS in patients receiving sorafenib treatment are independent prognostic factors for OS. These parameters can be used for assessment of treatment benefit and optimal treatment sequencing in patients with advanced HCC

Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC

The benefits of combined systemic and liver-directed treatments in inoperable intermediate- or advanced-stage hepatocellular carcinoma (HCC) have yet to be defined. This article presents the planned safety analyses for the first 40 patients randomized to radioembolization with yttrium-90 ((90) Y) resin microspheres followed by sorafenib (n = 20) or sorafenib only (n = 20) in the SORAMIC study.status: publishe

Advanced nanoarchitectures for solar photocatalytic applications

Advanced nanostructured materials that demonstrate useful activity under solar excitation in fields concerned with the elimination of pollutants, partial oxidation and the valorization of chemical compounds, water splitting and CO 2 reduction processes, are discussed. Point defects present in nanoparticulated anatase present both 5-fold- and 6-fold-coordinated titanium atoms, as well as 2-fold- and 3-fold-coordinated oxygens. The requirement of using sunlight as the excitation source for the degradation reaction demands, as a principal requirement, the modification of the electronic characteristics of a UV absorber system such as anatase-TiO 2. Some reports also indicate the need for large doping concentrations for N-doping in specific cases where notable changes in the valence band onset are subsequently observed. The effect of cetyltrimethylammonium bromide (CTAB) on the crystallization is reported by Yin et al. They showed that the presence of CTAB induces the appearance of BiOBr during the synthesis at 80°C using an aqueous method.Peer Reviewe